Processed Aloe vera gel ameliorates cyclophosphamide-induced immunotoxicity

Sun-A Im, Ki-Hyang Kim, Hee-Suk Kim, Ki-Hwa Lee, Eunju Shin, Seon-Gil Do, Tae Hyung Jo, Young In Park, Chong-Kil Lee, Sun-A Im, Ki-Hyang Kim, Hee-Suk Kim, Ki-Hwa Lee, Eunju Shin, Seon-Gil Do, Tae Hyung Jo, Young In Park, Chong-Kil Lee

Abstract

The effects of processed Aloe vera gel (PAG) on cyclophosphamide (CP)-induced immunotoxicity were examined in mice. Intraperitoneal injection of CP significantly reduced the total number of lymphocytes and erythrocytes in the blood. Oral administration of PAG quickly restored CP-induced lymphopenia and erythropenia in a dose-dependent manner. The reversal of CP-induced hematotoxicity by PAG was mediated by the functional preservation of Peyer's patch cells. Peyer's patch cells isolated from CP-treated mice, which were administered PAG, produced higher levels of T helper 1 cytokines and colony-stimulating factors (CSF) in response to concanavalin A stimulation as compared with those isolated from CP-treated control mice. PAG-derived polysaccharides directly activated Peyer's patch cells isolated from normal mice to produce cytokines including interleukin (IL)-6, IL-12, interferon-γ, granulocyte-CSF, and granulocyte-macrophage-CSF. The cytokines produced by polysaccharide-stimulated Peyer's patch cells had potent proliferation-inducing activity on mouse bone marrow cells. In addition, oral administration of PAG restored IgA secretion in the intestine after CP treatment. These results indicated that PAG could be an effective immunomodulator and that it could prevent CP-induced immunotoxic side effects.

Figures

Figure 1
Figure 1
Comparison of the molecular sizes of the polysaccharides in native Aloe vera gel (A) and in PAG (B).
Figure 2
Figure 2
Oral administration of PAG prevents and restores CP-induced lymphopenia and erythropenia. Mice (n = 10) were orally administered 200 or 400 mg/kg/day PAG for 19 days. Immunosuppression was induced by intraperitoneal (i.p.) injection of CP (25 mg/kg/day) for three consecutive days starting on the fourth day after PAG administration. The changes in the total numbers of leukocytes (A); lymphocytes (B); and erythrocytes (C) in the blood were examined on the indicated days. * indicates p < 0.05 and ** indicates p < 0.01.
Figure 3
Figure 3
Oral administration of PAG preserves the cytokine-producing capability of Peyer’s patch cells. Peyer’s patch cells were isolated from CP-treated mice that were administered PAG and were then stimulated with Con A for 4 days. Cytokine levels in the cell culture supernatants were measured by using enzyme-linked immunosorbent assays (ELISA). * indicates p < 0.05 and ** indicates p < 0.01.
Figure 4
Figure 4
Aloe polysaccharides induce hematopoietic cytokine production by Peyer’s patch cells. Peyer’s patch cells isolated from control mice were stimulated with Aloe polysaccharides for 3 days. The cytokine levels in the culture supernatants were determined by using ELISA. ** indicates p < 0.01, compared to PAG-untreated group.
Figure 5
Figure 5
Effects of cytokines produced by Peyer’s patch cells stimulated with the Aloe polysaccharides on the proliferation of bone marrow cells. Peyer’s patch cells isolated from control mice were stimulated with 100 μg/mL of polysaccharides for 3 days. The indicated amounts of the cytokine-containing cell culture supernatants (v/v %) were added to cultures of mouse bone marrow cells. ** indicates p < 0.01, compared to culture supernatant-untreated group.
Figure 6
Figure 6
Effect of oral administration of PAG on CP-suppressed IgA production in the intestine. Fresh feces from mice from each group were collected on days 3, 7, 11, 15, and 19. The feces were freeze-dried, weighed, and dissolved in phosphate-buffered saline containing protease inhibitors. Total IgA levels in fecal extracts were assessed by using an ELISA. * indicates p < 0.05 and ** indicates p < 0.01.

References

    1. Manna S., McAnalley B.H. Determination of the position of the O-acetyl group in a beta-(1–4)-mannan (acemannan) from Aloe barbardensis Miller. Carbohydr. Res. 1993;241:317–319. doi: 10.1016/0008-6215(93)80122-U.
    1. Yagi A., Makino K., Nishioka I., Kuchino Y. Aloe mannan, ploysaccharide, from Aloe arborescens var. natalensis. Planta Med. 1977;31:17–20.
    1. Gowda D.C., Neelisiddaiah B., Anjaneyalu Y.V. Structural studies of polysaccharides from Aloe vera. Carbohydr. Res. 1979;72:201–205. doi: 10.1016/S0008-6215(00)83936-1.
    1. Peng S.Y., Norman J., Curtin G., Corrier D., McDaniel H.R., Busbee D. Decreased mortality of Norman murine sarcoma in mice treated with the immunomodulator, Acemannan. Mol. Biother. 1991;3:79–87.
    1. Harris C., Pierce K., King G., Yates K.M., Hall J., Tizard I. Efficacy of acemannan in treatment of canine and feline spontaneous neoplasms. Mol. Biother. 1991;3:207–213.
    1. King G.K., Yates K.M., Greenlee P.G., Pierce K.R., Ford C.R., McAnalley B.H., Tizard I.R. The effect of acemannan immunostimulant in combination with surgery and radiation therapy on spontaneous canine and feline fibrosarcomas. J. Am. Anim. Hosp. Assoc. 1995;31:439–447. doi: 10.5326/15473317-31-5-439.
    1. Im S.A., Oh S.T., Song S., Kim M.R., Kim D.S., Woo S.S., Jo T.H., Park Y.I., Lee C.K. Identification of optimal molecular size of modified Aloe polysaccharides with maximum immunomodulatory activity. Int. Immunopharmacol. 2005;5:271–279.
    1. Sheets M.A., Unger B.A., Giggleman G.F., Jr., Tizard I.R. Studies of the effect of acemannan on retrovirus infections: clinical stabilization of feline leukemia virus-infected cats. Mol. Biother. 1991;3:41–45.
    1. Yates K.M., Rosenberg L.J., Harris C.K., Bronstad D.C., King G.K., Biehle G.A., Walker B., Ford C.R., Hall J.E., Tizard I.R. Pilot study of the effect of acemannan in cats infected with feline immunodeficiency virus. Vet. Immunol. Immunopathol. 1992;35:177–189. doi: 10.1016/0165-2427(92)90130-I.
    1. Saka W.A., Akhigbe R.E., Ishola O.S., Ashamu E.A., Olayemi O.T., Adeleke G.E. Hepatotherapeutic effect of Aloe vera in alcohol-induced hepatic damage. Pak. J. Biol. Sci. 2011;14:742–746. doi: 10.3923/pjbs.2011.742.746.
    1. Zhang L., Tizard I.R. Activation of a mouse macrophage cell line by acemannan: The major carbohydrate fraction from Aloe vera gel. Immunopharmacology. 1996;35:119–128. doi: 10.1016/S0162-3109(96)00135-X.
    1. Ramamoorthy L., Kemp M.C., Tizard I.R. Acemannan, a beta-(1,4)-acetylated mannan, induces nitric oxide production in macrophage cell line RAW 264.7. Mol. Pharmacol. 1996;50:878–884.
    1. Djeraba A., Quere P. In vivo macrophage activation in chickens with Acemannan, a complex carbohydrate extracted from Aloe vera. Int. J. Immunopharmacol. 2000;22:365–372. doi: 10.1016/S0192-0561(99)00091-0.
    1. Stuart R.W., Lefkowitz D.L., Lincoln J.A., Howard K., Gelderman M.P., Lefkowitz S.S. Upregulation of phagocytosis and candidicidal activity of macrophages exposed to the immunostimulant acemannan. Int. J. Immunopharmacol. 1997;19:75–82. doi: 10.1016/S0192-0561(97)00010-6.
    1. Im S.A., Lee Y.R., Lee Y.H., Lee M.K., Park Y.I., Lee S., Kim K., Lee C.K. In vivo evidence of the immunomodulatory activity of orally administered Aloe vera gel. Arch. Pharm. Res. 2010;33:451–456. doi: 10.1007/s12272-010-0315-1.
    1. Lee J.K., Lee M.K., Yun Y.P., Kim Y., Kim J.S., Kim Y.S., Kim K., Han S.S., Lee C.K. Acemannan purified from Aloe vera induces phenotypic and functional maturation of immature dendritic cells. Int. Immunopharmacol. 2001;1:1275–1284. doi: 10.1016/S1567-5769(01)00052-2.
    1. Young S.D., Whissell M., Noble J.C., Cano P.O., Lopez P.G., Germond C.J. Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors. Clin. Cancer Res. 2006;12:3092–3098. doi: 10.1158/1078-0432.CCR-05-2255.
    1. Slavin R.E., Millan J.C., Mullins G.M. Pathology of high dose intermittent cyclophosphamide therapy. Hum. Pathol. 1975;6:693–709. doi: 10.1016/S0046-8177(75)80078-5.
    1. Fishman P., Bar-Yehuda S., Barer F., Madi L., Multani A.S., Pathak S. The A3 adenosine receptor as a new target for cancer therapy and chemoprotection. Exp. Cell Res. 2001;269:230–236. doi: 10.1006/excr.2001.5327.
    1. Lohrmann H.P. The problem of permanent bone marrow damage after cytotoxic drug treatment. Oncology. 1984;41:180–184. doi: 10.1159/000225819.
    1. Wang M., Meng X.Y., Yang R.L., Qin T., Wang X.Y., Zhang K.Y., Fei C.Z., Li Y., Hu Y., Xue F.Q. Cordyceps militaris polysaccharides can enhance the immunity and antioxidation activity in immunosuppressed mice. Carbohydr. Polym. 2012;89:461–466. doi: 10.1016/j.carbpol.2012.03.029.
    1. Chen X., Nie W., Fan S., Zhang J., Wang Y., Lu J., Jin L. A polysaccharide from Sargassum fusiforme protects against immunosuppression in cyclophosphamide-treated mice. Carbohydr. Polym. 2012;90:1114–1119. doi: 10.1016/j.carbpol.2012.06.052.
    1. Mei Y.X., Chen H.X., Zhang J., Zhang X.D., Liang Y.X. Protective effect of chitooligosaccharides against cyclophosphamide-induced immunosuppression in mice. Int. J. Biol. Macromol. 2013;62:330–335. doi: 10.1016/j.ijbiomac.2013.09.038.
    1. Mowat A.M. Anatomical basis of tolerance and immunity to intestinal antigens. Nat. Rev. Immunol. 2003;3:331–341. doi: 10.1038/nri1057.
    1. Neutra M.R., Frey A., Kraehenbuhl J.P. Epithelial M cells: Gateways for mucosal infection and immunization. Cell. 1996;86:345–348. doi: 10.1016/S0092-8674(00)80106-3.
    1. Kelsall B. Recent progress in understanding the phenotype and function of intestinal dendritic cells and macrophages. Mucosal. Immunol. 2008;1:460–469. doi: 10.1038/mi.2008.61.
    1. Lee Y.-R., Lee Y.-H., Kim K.-H., Im S.-A., Lee C.-K. Induction of potent antigen-specific cytotoxic T cell response by PLGA-nanoparticles containing antigen and TLR agonist. Immune Netw. 2013;13:30–33. doi: 10.4110/in.2013.13.1.30.
    1. Macdonald T.T., Monteleone G. Immunity, inflammation, and allergy in the gut. Science. 2005;307:1920–1925. doi: 10.1126/science.1106442.
    1. Mosmann T.R., Kobie J.J., Lee F.E., Quataert S.A. T helper cytokine patterns: Defined subsets, random expression, and external modulation. Immunol. Res. 2009;45:173–184. doi: 10.1007/s12026-009-8098-5.
    1. Jansen J.H., Kluin-Nelemans J.C., Van D.J., Wientjens G.J., Willemze R., Fibbe W.E. Interleukin 6 is a permissive factor for monocytic colony formation by human hematopoietic progenitor cells. J. Exp. Med. 1992;175:1151–1154. doi: 10.1084/jem.175.4.1151.
    1. Lee C.K., Kim J.K., Kim Y., Lee M.K., Kim K., Kang J.K., Hofmeister R., Durum S.K., Han S.S. Generation of macrophages from early T progenitors in vitro in vitro. J. Immunol. 2001;166:5964–5969. doi: 10.4049/jimmunol.166.10.5964.
    1. Walker F., Zhang H.H., Matthews V., Weinstock J., Nice E.C., Ernst M., Rose-John S., Burgess A.W. IL6/sIL6R complex contributes to emergency granulopoietic responses in G-CSF- and GM-CSF-deficient mice. Blood. 2008;111:3978–3985. doi: 10.1182/blood-2007-10-119636.
    1. Yan B., Wei J.J., Yuan Y., Sun R., Li D., Luo J., Liao S.J., Zhou Y.H., Shu Y., Wang Q., et al. IL-6 cooperates with G-CSF to induce protumor function of neutrophils in bone marrow by enhancing STAT3 activation. J. Immunol. 2013;190:5882–5893. doi: 10.4049/jimmunol.1201881.
    1. Gee K., Guzzo C., Che Mat N.F., Ma W., Kumar A. The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm. Allergy Drug Targets. 2009;8:40–52. doi: 10.2174/187152809787582507.
    1. Santaolalla R., Abreu M.T. Innate immunity in the small intestine. Curr. Opin. Gastroenterol. 2012;28:124–129. doi: 10.1097/MOG.0b013e3283506559.
    1. Kim K., Kim H., Kwon J., Lee S., Kong H., Im S.A., Lee Y.H., Lee Y.R., Oh S.T., Jo T.H., et al. Hypoglycemic and hypolipidemic effects of processed Aloe vera gel in a mouse model of non-insulin-dependent diabetes mellitus. Phytomedicine. 2009;16:856–863. doi: 10.1016/j.phymed.2009.02.014.

Source: PubMed

3
Abonneren